Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

Patent metadata

Field	Value
Publication number	US-9802942-B2
Application number	US-201615199220-A
Country	US
Kind code	B2
Filing date	Jun 30, 2016
Priority date	Jul 1, 2015
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

Disclosed are new small molecules having a 4-methylpyrrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

First claim

We claim:

1. A compound or a salt or solvate thereof having Formula I:

wherein:
R 1 is hydrogen, an alkyl group, an alkylhydroxyl group, a carboxyl group, a 2,5-dioxopyrrolidinyl-1-yl-carboxylate group; an alkylamino group; an alkyl-N,N-dialkyl amino group; an alkyl-alkyoxy-amino group; an alkyl-alkyoxy-alkoxy-amino group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-morpholine group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-1-alkylpyrrolidine group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-cyclohexyl group; and an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-cyclobutyl group.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical carrier.

3. A method for treating a disease or disorder that is associated with glucocerebrosidase activity in a subject in need thereof, the method comprising administering the composition of claim 2 to the subject, wherein the disease or disorder is Gaucher's disease or Parkinson's disease.

4. The compound of claim 1 covalently attached to glucocerebrosidase.

5. A pharmaceutical composition comprising: (i) the compound of claim 1 covalently attached to glucocerebrosidase; and (ii) a pharmaceutical carrier.

6. A method for treating a disease or disorder that is associated with glucocerebrosidase activity in a subject in need thereof, the method comprising administering the composition of claim 5 to the subject, wherein the disease or disorder is Gaucher's disease or Parkinson's disease.

7. A compound or a salt or solvate thereof having a formula selected from:

8. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutical carrier.

9. A method for treating a disease or disorder that is associated with glucocerebrosidase activity in a subject in need thereof, the method comprising administering the composition of claim 8 to the subject, wherein the disease or disorder is Gaucher's disease or Parkinson's disease.

10. A compound or a salt or solvate thereof having Formula I:

wherein R 1 comprises a fluorophore selected from the group of fluorophores consisting of 5-carboxy-2,7-dichlorofluorescein; 5-Carboxyfluorescein (5-FAM); 5-Carboxytetramethylrhodamine (5-TAMRA); 5-FAM (5-Carboxyfluorescein); 5-ROX (carboxy-X-rhodamine); 6-Carboxyrhodamine 6G; 6-CR 6G; ALEXA FLUOR 350™ brand fluorophore; ALEXA FLUOR 430™ brand fluorophore; ALEXA FLUOR 488™ brand fluorophore; ALEXA FLUOR 532™ brand fluorophore; ALEXA FLUOR 546™ brand fluorophore; ALEXA FLUOR 568™ brand fluorophore; ALEXA FLUOR 594™ brand fluorophore; ALEXA FLUOR 633™ brand fluorophore; ALEXA FLUOR 647™ brand fluorophore; ALEXA FLUOR 660™ brand fluorophore; ALEXA FLUOR 680™ brand fluorophore; Bodipy 492/515; Bodipy 493/503; Bodipy 500/510; Bodipy 505/515; Bodipy 530/550; Bodipy 542/563; Bodipy 558/568; Bodipy 564/570; Bodipy 576/589; Bodipy 581/591; Bodipy 630/650-X; Bodipy 650/665-X; Bodipy 665/676; Bodipy FL; Bodipy FL ATP; Bodipy Fl-Ceramide; Bodipy R6G SE; Bodipy TMR; Bodipy TMR-X conjugate; Bodipy TMR-X, SE; Bodipy TR; Bodipy TR ATP; Bodipy TR-X SE; Carboxy-X-rhodamine (5-ROX); CY2™ brand fluorophore; CY3.1™ brand fluorophore; CY3.5™ brand fluorophore; CY3™ brand fluorophore; CY 5™ brand fluorophore; CY5.1™ brand fluorophore; CY5.5™ brand fluorophore; CY 7™ brand fluorophore; DCFH (Dichlorodihydrofluorescein Diacetate); DHR (Dihydorhodamine 123); Fluorescein (FITC); Fluorescein Diacetate; Fluoro-Gold (Hydroxystilbamidine); OREGON GREEN™ brand fluorophore; OREGON GREEN 488™ brand fluorophore; OREGON GREEN 488-X™ brand fluorophore; OREGON GREEN 500™ brand fluorophore; OREGON GREEN 514™ brand fluorophore; Rhodamine; Rhodamine 110; Rhodamine 123; Rhodamine 5 GLD; Rhodamine 6G; Rhodamine B; Rhodamine B 200; Rhodamine B extra; Rhodamine BB; Rhodamine BG; Rhodamine Green; Rhodamine Phallicidine; Rhodamine Phalloidin; Rhodamine Red; and Rhodamine WT, wherein the compound is fluorescent.

11. A composition comprising the compound of claim 10 .

12. A method of screening for a compound that binds to glucocerebrosidase, the method comprising contacting glucocerebrosidase with the compound of claim 10 and detecting fluorescence polarization, thereby detecting that the compound binds to glucocerebrosidase.

Assignees

• Univ Northwestern

Inventors

• Krainc Dimitri
• Silverman Richard B
• Zheng Jianbin

Classifications

• C12N9/2402

  hydrolysing O- and S- glycosyl compounds (3.2.1) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/465

  acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title

• A61K9/4866

  Organic macromolecular compounds · CPC title

• G01N2800/28

  Neurological disorders · CPC title